Improvement of brain function in hemodialysis patients treated with erythropoietin

Grimm, G; Stockenhuber, Felix; Schneeweiß, Bruno; Madl, Christian; Zeitlhofer, J.; Schneider, Barbara

doi:10.1038/ki.1990.229

Cited by 150 publications

(96 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, in uncontrolled studies of patients receiving hemodialysis, amelioration of severe anemia with erythropoietin is associated with improvement in cognitive function (29,30). In this study, low hemoglobin levels were significantly correlated with cognitive impairment and attenuated the association of eGFR with cognitive impairment.…”

Section: Discussionmentioning

confidence: 58%

Vascular Risk Factors and Cognitive Impairment in Chronic Kidney Disease

Tamura

Xie

Yaffe

et al. 2011

Clinical Journal of the American Society of Nephrology

130

View full text Add to dashboard Cite

SummaryBackground and objectives Cognitive impairment is common among persons with chronic kidney disease, but the extent to which nontraditional vascular risk factors mediate this association is unclear.Design, setting, participants, & measurements We conducted cross-sectional analyses of baseline data collected from adults with chronic kidney disease participating in the Chronic Renal Insufficiency Cohort study. Cognitive impairment was defined as a Modified Mini-Mental State Exam score Ͼ1 SD below the mean score.Results Among 3591 participants, the mean age was 58.2 Ϯ 11.0 years, and the mean estimated GFR (eGFR) was 43.4 Ϯ 13.5 ml/min per 1.73 m 2 . Cognitive impairment was present in 13%. After adjustment for demographic characteristics, prevalent vascular disease (stroke, coronary artery disease, and peripheral arterial disease) and traditional vascular risk factors (diabetes, hypertension, smoking, and elevated cholesterol), an eGFR Ͻ30 ml/min per 1.73 m 2 was associated with a 47% increased odds of cognitive impairment (odds ratio 1.47, 95% confidence interval 1.05, 2.05) relative to those with an eGFR 45 to 59 ml/ min per 1.73 m 2 . This association was attenuated and no longer significant after adjustment for hemoglobin concentration. While other nontraditional vascular risk factors including C-reactive protein, homocysteine, serum albumin, and albuminuria were correlated with cognitive impairment in unadjusted analyses, they were not significantly associated with cognitive impairment after adjustment for eGFR and other confounders. ConclusionsThe prevalence of cognitive impairment was higher among those with lower eGFR, independent of traditional vascular risk factors. This association may be explained in part by anemia.

show abstract

Section: Discussionmentioning

confidence: 58%

Vascular Risk Factors and Cognitive Impairment in Chronic Kidney Disease

Tamura

Xie

Yaffe

et al. 2011

Clinical Journal of the American Society of Nephrology

130

View full text Add to dashboard Cite

show abstract

“…Similar results were reported from studies on cognitive functions in chronic dialysis patients receiving epoetin-a. Two studies described significant relationship between hemoglobin levels and ERP P300 latency scores [14][15][16][17][18]. However, in that study cognitive dysfunction, which seems correlated with low hemoglobin values does not recover completely even in the patients with normal hemoglobin levels.…”

Section: Discussionmentioning

confidence: 89%

“…Studies on the effects of epoetin-a administration on cognitive functions in patients with end-stage kidney failure have shown improvement of neuropsyhiatric indices of cognitive functions and electroencephalographical measures of ERP after the institution of epoetin-a [12][13][14][15][16][17][18][19].…”

Section: Discussionmentioning

confidence: 99%

Cognitive dysfunction in β‐thalassemia minor

et al. 2006

View full text Add to dashboard Cite

Turkey b-thalassemia minor is a common, hereditary, and mostly symptomless disease. Previous studies have shown that lower hemoglobin values are associated with poorer cognitive functions. We aimed to evaluate the cognitive function in patients with b-thalassemia minor. Thirty-two male subjects with b-thalassemia minor and 32 sex-, age-, and education statusmatched healthy subjects were enrolled in the study. Blood tests and P300 potentials were carried out. P300 potential latency in all patients was significantly longer than those in the control group (337.63 ± 34.89 msec and 310.66 ± 14.30 msec, respectively; t 4.046, P < 0.001). The amplitudes of P300 in patient group were significantly lower than those in the control group (5.19 ± 3.59 lV and 9.81 ± 3.33 lV, respectively; t 5.349, P < 0.001). In this study, we have found that P300 potentials are adversely affected for cognitive functions in patients with b-thalassemia minor. Am. J. Hematol. 82:203-207, 2007. V V C 2006 Wiley-Liss, Inc.

show abstract

“…For example, anemia is thought to be a key mediator of cognitive impairment in people with ESRD (22,23) and more recently has been associated with cognitive impairment in elderly individuals without known kidney disease (24). Inflammatory mechanisms have been implicated in the pathogenesis of vas- (25) and have been prospectively associated with cognitive decline (12).…”

Section: Discussionmentioning

confidence: 99%

Chronic Kidney Disease and Cognitive Impairment in the Elderly

Kurella¹,

Chertow²,

Fried³

et al. 2005

Journal of the American Society of Nephrology

418

376

View full text Add to dashboard Cite

T he prevalence of cognitive impairment and dementia in ESRD is more than double that of the general population (1-3). However, the reasons for this high rate remain uncertain. Specifically, it is not known whether cognitive impairment is mediated by the direct effects of uremia, per se, or is attributable to a high prevalence of predisposing risk factors among individuals with ESRD and side effects of the hemodialysis treatment. Recent studies suggest that chronic kidney disease (CKD) may also be a risk factor for cognitive impairment (4 -6). Many of the factors that have been proposed as mediators of cognitive impairment in ESRD, such as anemia and inflammation, may be present in individuals with earlier stages of CKD (7,8).CKD has been associated with an increased risk for dementia in elderly individuals (4) and with poorer performance on tests of global cognitive function, executive function, language, and memory (5,6). However, previous studies were conducted in mostly white populations and did not explore several hypothesized mediators of impairment, such as anemia and inflammation. Moreover, no studies have examined the association between CKD and performance on serial cognitive function tests, and only one study stratified analyses by the severity of CKD (6). The goals of this study were to determine the strength of the association between CKD and cognitive function in a biracial cohort of community-dwelling elderly and to explore potential mediators of cognitive impairment and whether these extinguish or otherwise modify the association between CKD and cognitive impairment. We hypothesized that CKD would be associated with cognitive impairment in cross-sectional and longitudinal analyses and that the association would be "dose (severity)-dependent" and independent of established risk factors for cognitive impairment, such as age, low educational attainment, diabetes, hypertension, and other cardiovascular disease risk factors.

show abstract

Improvement of brain function in hemodialysis patients treated with erythropoietin

Cited by 150 publications

References 29 publications

Vascular Risk Factors and Cognitive Impairment in Chronic Kidney Disease

Vascular Risk Factors and Cognitive Impairment in Chronic Kidney Disease

Cognitive dysfunction in β‐thalassemia minor

Chronic Kidney Disease and Cognitive Impairment in the Elderly

Contact Info

Product

Resources

About